For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Bisphosphonates - Independent medicine & health information for consumers & professionals Bisphosphonates — medicine information
Latest independent drug information about bisphosphonates and treatments, written and reviewed by experts in Australia.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Denosumab (Prolia) for postmenopausal osteoporosis | Information about denosumab, a new biological agent for the treatment of postmenopausal osteoporosis. | Professional publication - NPS RADAR - Review | Health Professionals | 2010-12-01 00:00:00 |
| Zoledronic acid (Aclasta) for osteoporosis | Information about use of Zoledronic acid (Aclasta) in established osteoporosis | Professional publication - NPS RADAR - Review | Health Professionals | 2009-04-01 00:00:00 |
| Risedronate (Actonel Once-a-month) and summary of anti-resorptive drug listings | Summary of PBS listed anti-resorptive drugs for osteoporosis including the new listing for once-monthly risedronate tablets. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2009-08-01 00:00:00 |
| Extended PBS listings for zoledronic acid 5mg (Aclasta) | Extended PBS listings for zoledronic acid 5mg (Aclasta) effective 1 April 2010. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2010-04-01 00:00:00 |
| Case study 49 report: Reducing risk of osteoporotic fractures | Elderly patient diagnosed with osteoporosis, confirmed by BMD after X-ray showed 2 vertebral fractures. Had an early menopause and has family history of breast cancer. | Professional activity - Case study report | Health Professionals | 2007-10-01 00:00:00 |
| Case study 49: Reducing risk of osteoporotic fractures | Elderly patient diagnosed with osteoporosis, confirmed by BMD after X-ray showed 2 vertebral fractures. Had an early menopause and has family history of breast cancer. | Professional activity - Case study | Health Professionals | 2007-08-01 00:00:00 |
| Case study 69: Osteoporosis | Bill, a 72-year-old retired train driver, was discharged from hospital 6 months ago after recovering from a fractured hip caused when his foot caught on a floor mat | Professional activity - Case study | Health Professionals | 2011-06-01 00:00:00 |
| Incidence and avoidance of osteonecrosis of the jaw associated with use of bisphosphonates | Information on osteonecrosis of the jaw associated with bisphosphonate use in osteoporosis, Paget's disease and malignancy. Risk factors such as dental extraction are discussed. | Professional publication - NPS factsheet | Health Professionals | 2007-12-12 00:00:00 |
| Osteoporotic fracture prevention | Ways to identify and modify risks associated with osteoporosis and fractures in men and women. Drug therapy includes HRT, oestrogen receptor modulators and bisphosphonates | Professional publication - NPS News | Health Professionals | 2003-02-01 00:00:00 |
| Preventing osteoporosis and reducing risk of fracture | Information on preventing osteoporosis and reducing fracture risk through the use of physical activity, adequate calcium and vitamin D, and the use of anti-osteoporotic drugs, with bisphosphonates as first-line therapy. | Professional publication - Prescribing Practice Review | Health Professionals | 2007-09-01 00:00:00 |
| NPS RADAR helps prescribers navigate decision-making | Prescribers considering use of zoledronic acid (Aclasta) once-yearly infusion in patients who have osteoporosis will need to weigh up the possible benefits against the relative lack of experience with this drug in osteoporosis. | Media release | Others | 2008-12-08 00:00:00 |
| NPS issues new fact sheet on Osteonecrosis of the Jaw | Osteonecrosis of the jaw a possible side effect of taking bisphosphonates (for trade press). | Media release | Others | 2007-12-14 00:00:00 |
| NPS issues new fact sheet on Osteonecrosis of the Jaw | Jaw disease associated with osteoporosis medicines group bisphosphonates. | Media release | Others | 2007-12-16 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
